At the 2022 Annual Congress of the European Hematology Association, researchers from the Spanish National Cancer Institute reported how high levels of the RNA-binding protein hnRNP-K could lead to bone marrow failure.
Singapore’s Agency for Science, Technology and Research (A*STAR) has inked a deal with Boehringer Ingelheim GmbH to develop and commercialize targeted cancer therapies.
RSS
